Medi-Tate

History

2021: Olympus has bought a Tri-Tate

At the end of May 2021, Olympus acquired Tri-Tate, a developer of devices for the treatment of benign prostatic hyperplasia (BPH). The financial terms of the transaction are not disclosed.

The Israeli company Tri-Tate produces the device iTind - a flexible tool from nitinol with three posts, which can be placed in the urinary canal during one procedure. The tool gradually expands over five days, creating channels for urine outflow and changing the shape of the prostate. The Tri-Tate was labeled "CE" in Europe in 2012.

Olympus Bought Adenoma Device Developer Simple

Medi-Tate]]

In 2018, Olympus received the exclusive right to distribute Bri-Tate products in the United States through strategic investments, and also secured the right to sell the iTind device in the United States from April 2020.

The acquisition of Sound-Tate is consistent with our corporate strategy, in which the company focuses on three priority therapeutic areas - gastroenterological endotherapy devices, urological devices and respiratory endotherapy devices, "said Olympus Chief Operating Officer Nacho Abia in a press release. -Invention-based Tri-Tate products offer a minimally invasive treatment option and provide outpatient care.

Intermediate-Tate CEO Ido Kilemnik added that Olympus "praised" the work done by the Tri-Tate team and the focus on long-term clinical outcomes.

We are pleased to join Olympus, which shares our vision and no less wants to turn iTind into an international standard of care for prostate adenoma, "said Ido Kilemnik. - We are pleased to cooperate with Olympus and hope to continue working to improve the quality of life of patients.[1]

Notes